A group of institutional investors from Nomura, BMO, GAM and more than 60 others representing trillions in assets are now calling on Covid-19 vaccine developers to tie their executive pay to ensure vaccines are available in the world. world.
“It is clear that today a large part of the world’s population still does not have sufficient and equitable access to vaccines,” the investors said, explaining their reasoning behind Thursday’s letter to executives at Pfizer, Moderna, AstraZeneca and NOT A WORD.
The push comes as all companies have pledged to make cheaper versions of their vaccines available, but many countries still lack essential supplies. WHO has sought to reach the 70% vaccinated mark in all countries after nearly half of its participating member countries failed to reach 40% vaccinated by 2021, according to the Financial Time.
House Republican calls for Omicron treatment hearing
Representative Michael Burgess (R-TX) is request a hearing with federal political leaders to better understand how Congress can improve the U.S. response, including through the distribution of effective treatments, to combat the new Omicron variant, according to a letter sent yesterday to House Energy & Commerce committee chairman Frank Pallone ( D -NEW JERSEY).
“It would be beneficial to invite various agencies such as the Centers for Disease Control and Prevention, the Food and Drug Administration and the Biomedical Advanced Research and Development Authority to testify on the process of development of COVID-19 therapeutics and antivirals, such as molnupiravir. and sotrovimab, and how we can ensure adequate distribution of these options, ”he wrote.
Burgess also noted that due to its expected effectiveness against the Omicron variant, shipments of GlaxoSmithKline and sotrovimab from Vir were halted to ensure that supplies were not depleted as the variant spread. “Although this decision has since been overturned, I am very concerned about the limited supply currently available,” he wrote.
The Senate Committee on Health is established meet Next Tuesday to hear from CDC, FDA and NIH officials, including Acting FDA Commissioner Janet Woodcock and President Biden’s senior medical adviser Tony Fauci.
Manufacturing difficulties mean there will be many more pill from Merck than from Pfizer in the coming months
Until at least March, the United States will have hundreds of thousands of additional treatments of the Merck pill to treat Covid-19, known as molnupiravir, than the Pfizer Paxlovid pill, even as the United States United bought 20 million pills from Pfizer.
Part of the reason for this early discrepancy is that while the Pfizer pill may be more effective than the Merck pill (no one has conducted a face-to-face trial), the Pfizer pill is also difficult to control. to manufacture.
Chemist Derek Lowe wrote in Science recently on how and why the Pfizer pill is difficult to manufacture, and how there are shortages of the reagents used to make it.
“So there is a shortage of stuff, which is used to make the stuff, which is used to make the stuff, which is used to make two of the starting materials for Paxlovid. And that’s just one of the reagents, “he wrote.” Remember, as complicated as it sounds, setting up a production supply chain is much more than that! It all means when someone says’ Oh, we can just make Paxlovid in plants all over the world, “he left out the rest of the sentence, which is” “… if we can get the raw materials.”
White House coronavirus response coordinator Jeff Zients also recently told a press briefing that the United States is offering anything it can to help Pfizer, but the complex chemistry involved in creating of the active ingredient in the pill means that production takes around six to eight months.